Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants
Nicholas A. Marston, Shinwan Kany, Giorgio E. M. Melloni, Sean J. Jurgens, Frederick K. Kamanu, Yi-Pin Lai, Joel T. Rämö, Itamar Raz, Stephen D. Wiviott, Patrick T. Ellinor, Marc S. Sabatine, Christian T. Ruff · 2026
Read Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants by Nicholas A. Marston, Shinwan Kany, Giorgio E. M. Melloni, Sean J. Jurgens, Frederick K. Kamanu, Yi-Pin Lai, Joel T. Rämö, Itamar Raz, Stephen D. Wiviott, Patrick T. Ellinor, Marc S. Sabatine, Christian T. Ruff (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13278951.txt.
Description
Nicholas A Marston and colleagues test a diabetes drug's heart protection in people carrying cardiomyopathy gene variants, in a 2026 analysis. Genetic data came from the DECLARE-TIMI 58 trial of dapagliflozin in type 2 diabetes. Whether carriers of heart muscle disease variants gain extra benefit was unknown.
Sequencing covered 12,685 trial participants, and 121 carried a harmful variant in a high-confidence cardiomyopathy gene. Most carriers had never had heart failure before the trial. Dapagliflozin cut hospitalisation for heart failure far more sharply in carriers than in non-carriers. The absolute gain reached about thirteen percentage points in carriers. The authors propose early treatment for carriers and call for a dedicated prospective trial.
Catalog record
| CREATOR | Nicholas A. Marston, Shinwan Kany, Giorgio E. M. Melloni, Sean J. Jurgens, Frederick K. Kamanu, Yi-Pin Lai, Joel T. Rämö, Itamar Raz, Stephen D. Wiviott, Patrick T. Ellinor, Marc S. Sabatine, Christian T. Ruff |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |